Academic literature on the topic '11C-THK5351'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '11C-THK5351.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "11C-THK5351"

1

Miyake, Keisuke, Daisuke Ogawa, and Tetsuhiro Hatakeyama. "STMO-5 Utilization of intraoperative multimodal technologies [PET and 5-ALA] for treating glioblastoma." Neuro-Oncology Advances 3, Supplement_6 (2021): vi12. http://dx.doi.org/10.1093/noajnl/vdab159.044.

Full text
Abstract:
Abstract Background: We can improve prognosis of glioblastoma by using positron emission tomography (PET) scans to guide them in removing tumors, and intraoperative magnetic resonance imaging (IoMRI) and 5-aminolevulinic acid (5-ALA) for identifying residual tumors. Tau proteins are reported to accumulate in glioblastomas, so we compared the efficacy of their PET tracer, THK5351, against that of 11C-MET, 18F-FLT, and 18F-FMISO. Methods: Patients (n = 11) underwent scans between February 2020 and July 2021 for glioblastoma resection. Tumor-to-normal tissue accumulation ratio (TNR) and accumulat
APA, Harvard, Vancouver, ISO, and other styles
2

Hatano, Keiko, Kenji Ishibashi, Kazuki Yamada, Kenji Ishii, and Atsushi Iwata. "Clinical Application of 18F-THK5351 PET to Identify Inflammatory Lesions Through Imaging Astrogliosis in a Case of Cytomegalovirus Ventriculoencephalitis." Clinical Nuclear Medicine 48, no. 10 (2023): e489-e490. http://dx.doi.org/10.1097/rlu.0000000000004809.

Full text
Abstract:
Abstract 18F-THK5351 PET is used to estimate the degree of astrogliosis. Because inflammatory lesions usually accompany astrogliosis, 18F-THK5351 PET is potentially worthy of clinical application in inflammatory disorders. Here, we report a case of cytomegalovirus ventriculoencephalitis in an immunocompromised 75-year-old woman who underwent 18F-THK5351 PET and conventional neuroimaging modalities, including 11C-methionine, 18F-FDG, and MRI. 18F-THK5351 PET was clearly superior to the other modalities in identifying inflammatory lesions and can therefore be a useful marker for identifying infl
APA, Harvard, Vancouver, ISO, and other styles
3

Nihashi, Takashi, Keita Sakurai, Takashi Kato, et al. "Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer’s Disease Continuum." Journal of Alzheimer's Disease 85, no. 1 (2022): 223–34. http://dx.doi.org/10.3233/jad-215024.

Full text
Abstract:
Background: Alzheimer’s disease (AD) is conceptualized as a biological continuum encompassing the preclinical (clinically asymptomatic but with evidence of AD pathology) and clinical (symptomatic) phases. Objective: Using 18F-THK5351 as a tracer that binds to both tau and monoamine oxidase B (MAO-B), we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET. Methods:
APA, Harvard, Vancouver, ISO, and other styles
4

Ota, Miho, Noriko Sato, Moto Nakaya, et al. "Relationship between the tau protein and choroid plexus volume in Alzheimer’s disease." NeuroReport 34, no. 11 (2023): 546–50. http://dx.doi.org/10.1097/wnr.0000000000001923.

Full text
Abstract:
Tau protein accumulation in the brain is thought to be one of the causes of Alzheimer’s disease (AD). Recent studies found that the choroid plexus (CP) has a role in β-amyloid and tau protein clearance in the brain. We evaluated the relationships between CP volume and the ß-amyloid and tau protein depositions. Participants were 20 patients with AD and 35 healthy subjects who underwent MRI and PET scanning using the ß-amyloid tracer 11C-PiB and the tau/inflammatory tracer 18F-THK5351. We computed the volume of the CP and estimated the relationships between the CP volume and ß-amyloid and tau pr
APA, Harvard, Vancouver, ISO, and other styles
5

Chiotis, Konstantinos, Per Stenkrona, Ove Almkvist, et al. "Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain." European Journal of Nuclear Medicine and Molecular Imaging 45, no. 9 (2018): 1605–17. http://dx.doi.org/10.1007/s00259-018-4012-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Higashihara, Mana, Kenji Ishibashi, Aya M. Tokumaru, Kenji Ishii, and Atsushi Iwata. "Brain PET Imaging of 11C-Methionine, 18F-FDG, and 18F-THK5351 in a Case of Lymphomatoid Granulomatosis." Clinical Nuclear Medicine 47, no. 12 (2022): e749-e751. http://dx.doi.org/10.1097/rlu.0000000000004388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lemoine, Laetitia, Per-Göran Gillberg, Marie Svedberg, et al. "Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains." Alzheimer's Research & Therapy 9, no. 1 (2017): 96. https://doi.org/10.1186/s13195-017-0325-z.

Full text
Abstract:
<strong>Background: </strong>The aim of this study was to compare the binding properties of several tau positron emission tomography tracers—THK5117, THK5351, T807 (also known as AV1451; flortaucipir), and PBB3—head to head in the same human brain tissue.<strong>Methods: </strong>Binding assays were performed to compare the regional distribution of <sup>3</sup>H-THK5117 and <sup>3</sup>H-THK5351 in postmortem tissue from three Alzheimer's disease (AD) cases and three control subjects in frontal and temporal cortices as well as in the hippocampus. Competition binding assays between THK5351, THK
APA, Harvard, Vancouver, ISO, and other styles
8

Shidahara, Miho, Benjamin A. Thomas, Nobuyuki Okamura, et al. "A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB." Annals of Nuclear Medicine 31, no. 7 (2017): 563–69. http://dx.doi.org/10.1007/s12149-017-1185-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ishibashi, Kenji, Masashi Kameyama, Yoshiharu Miura, Jun Toyohara, and Kenji Ishii. "Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders." Clinical Nuclear Medicine 46, no. 1 (2020): e31-e33. http://dx.doi.org/10.1097/rlu.0000000000003197.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mitamura, Katsuya, Takashi Norikane, Yuka Yamamoto, Keisuke Miyake, and Yoshihiro Nishiyama. "Increased Uptake of 18F-THK5351 in Glioblastoma But Not in Metastatic Brain Tumor." Clinical Nuclear Medicine, April 18, 2025. https://doi.org/10.1097/rlu.0000000000005909.

Full text
Abstract:
18F-THK5351 was developed as a tracer with high binding affinity and selectivity for tau protein. However, its off-target binding to monoamine oxidase B (MAO-B), an enzyme highly expressed in astrocytes, has also been demonstrated. In the case of glioblastoma, a strong accumulation of both 11C-methionine (MET) and 18F-THK5351 was observed in the tumor. Conversely, in the case of metastatic brain tumor, while 11C-MET PET showed strong uptake in the lesion, 18F-THK5351 PET revealed no significant accumulation. Differentiating solitary metastatic brain tumors from glioblastoma on MRI can be chall
APA, Harvard, Vancouver, ISO, and other styles
More sources
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!